Long-term oral contraceptive use as a risk factor for high-grade cervical lesions in women with high-risk human papillomavirus: a retrospective cohort analysis
Authors:
- 5 September 2025
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (11) , 102650
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Human Papillomavirus Vaccination and Cervical Cancer RiskObstetrical & Gynecological Survey, 2023
- The association of cervicovaginal Langerhans cells with clearance of human papillomavirusFrontiers in Immunology, 2022
- Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated IssueAnticancer Research, 2020
- Evidence of Passive Smoking as a Risk Factor of High-Grade Squamous Intraepithelial Lesion: A Case-Control StudyBiological and Pharmaceutical Bulletin, 2020
- Pharmacodynamics of combined estrogen–progestin oral contraceptives: 4. Effects on uterine and cervical epitheliaExpert Review of Clinical Pharmacology, 2020
- Langerhans Cells Orchestrate the Protective Antiviral Innate Immune Response in the Lymph NodeCell Reports, 2019
- Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse ModelThe American Journal of Pathology, 2019
- Interaction between 17β-estradiol, prolactin and human papillomavirus induce E6/E7 transcript and modulate the expression and localization of hormonal receptorsCancer Cell International, 2019
- Abstract 2202: Long term risk prediction of p16/Ki-67 dual stain in triage of HPV-positive womenCancer Research, 2018
- Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studiesThe Lancet, 2007